In triple-negative breast cancer, CCL5 expression has also been correlated with residual tumor size and tumor infiltrating lymphocytes after neoadjuvant chemotherapy (Araujo et al., 2018). This evidence concerns the gene CCL5 and triple-negative breast carcinoma.